头孢他啶-阿维巴坦在治疗耐碳青霉烯类肺炎克雷伯菌血症方面优于其他治疗方案。
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
作者信息
Shields Ryan K, Nguyen M Hong, Chen Liang, Press Ellen G, Potoski Brian A, Marini Rachel V, Doi Yohei, Kreiswirth Barry N, Clancy Cornelius J
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
Abstract
There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant bacteremia was associated with higher rates of clinical success ( = 0.006) and survival ( = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity ( = 0.002).
摘要
目前尚无数据比较头孢他啶-阿维巴坦与其他对照药物治疗耐碳青霉烯类感染患者的疗效。在我们中心，与其他治疗方案相比，用头孢他啶-阿维巴坦治疗耐碳青霉烯类菌血症的临床成功率（P = 0.006）和生存率（P = 0.01）更高。在各个治疗组中，基础疾病、疾病严重程度、菌血症来源或菌株特征（97%产生碳青霉烯酶）均无差异。含氨基糖苷类和黏菌素的治疗方案与肾毒性发生率增加相关（P = 0.002）。
相似文献
1
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.头孢他啶-阿维巴坦在治疗耐碳青霉烯类肺炎克雷伯菌血症方面优于其他治疗方案。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
2
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.头孢他啶-阿维巴坦治疗持续中性粒细胞减少兔产碳青霉烯酶肺炎克雷伯菌肺炎的药代动力学和疗效。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02157-19.
3
Evolution of Under the Pressure of Carbapenems and Ceftazidime/Avibactam in a Patient With Persistent Bacteremia Caused by .碳青霉烯类和头孢他啶/阿维巴坦压力下导致持续菌血症的 患者的演变。
J Korean Med Sci. 2024 Jul 1;39(25):e208. doi: 10.3346/jkms.2024.39.e208.
4
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
5
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.产 OXA-48 碳青霉烯酶肠杆菌科细菌感染患者应用头孢他啶-阿维巴坦治疗的临床特征和预后
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
6
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
7
Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales.产碳青霉烯酶肺炎克雷伯菌和头孢他啶-阿维巴坦快速分子检测对碳青霉烯类耐药肠杆菌科菌血症患者结局的影响。
Clin Infect Dis. 2022 Dec 19;75(12):2066-2075. doi: 10.1093/cid/ciac354.
8
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
9
Changing Characteristics and Susceptibility to Ceftazidime/Avibactam of Bloodstream Extensively Drug-Resistant from a Greek Intensive Care Unit.希腊重症监护病房血流感染的广泛耐药对头孢他啶/阿维巴坦的耐药特征及敏感性变化
Microb Drug Resist. 2020 Jan;26(1):28-37. doi: 10.1089/mdr.2019.0090. Epub 2019 Aug 6.
10
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.头孢他啶-阿维巴坦挽救治疗产碳青霉烯酶肺炎克雷伯菌引起的感染患者的疗效。
Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492.
引用本文的文献
1
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.头孢他啶-阿维巴坦用于重症患者：一项多中心观察性研究。
Antibiotics (Basel). 2025 Aug 5;14(8):797. doi: 10.3390/antibiotics14080797.
2
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study.头孢他啶-阿维巴坦治疗耐碳青霉烯类微生物：一项前瞻性、观察性、单中心研究。
Antibiotics (Basel). 2025 Jul 31;14(8):773. doi: 10.3390/antibiotics14080773.
3
A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection.一项初步临床研究：黏菌素联合头孢他啶/阿维巴坦治疗耐碳青霉烯类革兰阴性杆菌感染
Infect Drug Resist. 2025 Aug 9;18:3977-3991. doi: 10.2147/IDR.S542467. eCollection 2025.
4
Evaluation of Infections Caused by Carbapenem-Resistant , , and in an Intensive Care Unit: A Retrospective Study.重症监护病房中耐碳青霉烯类[细菌名称缺失]和[细菌名称缺失]引起的感染评估：一项回顾性研究
Antibiotics (Basel). 2025 Jul 12;14(7):700. doi: 10.3390/antibiotics14070700.
5
Prognosis and Outcome of Carbapenem-Resistant Enterobacterales Bacteremia Managed With Ceftazidime-Avibactam and Aztreonam Combination Therapy in Tawam Hospital, UAE: A Retrospective Study.阿联酋塔瓦姆医院采用头孢他啶-阿维巴坦与氨曲南联合治疗耐碳青霉烯类肠杆菌科菌血症的预后及结局：一项回顾性研究
Cureus. 2025 Jun 10;17(6):e85689. doi: 10.7759/cureus.85689. eCollection 2025 Jun.
6
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant versus .耐碳青霉烯类所致菌血症血液病患者临床结局的比较分析 与……相对比 （原文此处不完整）
Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025.
7
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性：新型β-内酰胺酶抑制剂（阿维巴坦、瓦博巴坦、瑞来巴坦）抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
8
Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia.头孢他啶-阿维巴坦与多粘菌素B治疗医院获得性和呼吸机相关性细菌性肺炎的经济学评价
Braz J Infect Dis. 2025 May 14;29(4):104545. doi: 10.1016/j.bjid.2025.104545.
9
Temporal Trends in the Management and Mortality Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales: A Cohort Study.产肺炎克雷伯菌碳青霉烯酶肠杆菌科细菌感染的管理及死亡率的时间趋势：一项队列研究
Cureus. 2025 Apr 8;17(4):e81902. doi: 10.7759/cureus.81902. eCollection 2025 Apr.
10
Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant (CRE) of Various Carbapenemase Phenotypes in Southwestern China.氨曲南作为头孢他啶/阿维巴坦对中国西南部多种碳青霉烯酶表型的耐碳青霉烯肠杆菌科细菌（CRE）的增效剂。
Infect Drug Resist. 2025 May 3;18:2243-2253. doi: 10.2147/IDR.S523498. eCollection 2025.
本文引用的文献
1
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
2
Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.美国碳青霉烯类耐药肠杆菌科细菌（CRE）感染中心地区耐碳青霉烯类肠杆菌科细菌（CRE）所致菌血症的多中心临床与分子流行病学分析
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02349-16. Print 2017 Apr.
3
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
4
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.头孢他啶-阿维巴坦作为耐碳青霉烯类微生物所致感染的挽救治疗药物
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01964-16. Print 2017 Feb.
5
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
6
Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌血症
Clin Infect Dis. 2016 Oct 15;63(8):1147-8. doi: 10.1093/cid/ciw491. Epub 2016 Jul 17.
7
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.由产 KPC 肺炎克雷伯菌引起的感染：一项多中心研究中的治疗和死亡率差异。
J Antimicrob Chemother. 2015 Jul;70(7):2133-43. doi: 10.1093/jac/dkv086. Epub 2015 Apr 21.
8
Treating infections caused by carbapenemase-producing Enterobacteriaceae.治疗产碳青霉烯酶肠杆菌科细菌感染。
Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12.
9
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.产碳青霉烯酶肺炎克雷伯菌血流感染：通过联合抗生素方案降低死亡率及碳青霉烯类药物的作用
Antimicrob Agents Chemother. 2014;58(4):2322-8. doi: 10.1128/AAC.02166-13. Epub 2014 Feb 10.
10
Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.移植受者碳青霉烯类耐药肺炎克雷伯菌菌血症的流行病学和分子特征。
Am J Transplant. 2013 Oct;13(10):2619-33. doi: 10.1111/ajt.12424. Epub 2013 Sep 6.
Zotero 插件